Ann: SCENESSE launched in Europe-CUV.AX, page-12

I agree that on market cap Clinuvel must be a chance and I also agree that the lack of liquidity will work against entry. Over the last 6 months the average daily turnover has been just over 20,000 shares, that is 0.04% shares traded per day. AJX, a recent entry to the ASX300, currently has a lower market cap but 0.22% shares traded per day. I am still hopeful that the lack of liquidity will eventually work in current holders favour as if there is ever some real interest the share price may rise steeply and strongly.

The other aspect is that following ASX All Ords inclusion in March 15 Clinuvel’s share price went down 20% and then sideways for 12 months. Positive cash flows and FDA approval will generate a lot more interest than ASX 300 inclusion. Not saying ASX300 it is a bad thing but if Clinuvel is included I wouldn't expect any real change to the share price or trading pattern.